TY - JOUR
T1 - Clinical and immunologic effects of autologous lymph node cell transplant in chronic fatigue syndrome
AU - Klimas, N. G.
AU - Patarca-Montero, R.
AU - Maher, K.
AU - Smith, M.
AU - Bathe, O.
AU - Fletcher, M. A.
N1 - Funding Information:
This work was supported, in part, by a grant from the CFIDS Association of America, by NIH Center Grant 1UD1-AI 45940-02, and by funds from Neoprobe Corp. and Ciratech Corp.
PY - 2001
Y1 - 2001
N2 - An open labeled, phase 1, safety and feasibility study using lymph node extraction, ex vivo lymph node cell expansion, followed by autologous cell reinfusion was evaluated as a potential immunomodulatory treatment strategy in patients with chronic fatigue syndrome (CFS). The experimental therapy utilized the cells of the lymph node, activated and grown in culture with defined media, interleukin-2 (IL-2) and anti-CD3 to activate and enhance cellular immunological functions. This procedure was designed to change the cytokine pattern of the lymph node lymphocytes to favor expression of T-helper (Th)1-type over Th2-type cytokines. The mixed population of ex vivo immune-enhanced cells were reinfused into the donor, who was carefully monitored for adverse events and possible clinical benefit. There were no adverse events. There were significant improvements in clinical status in association with a significant decrease in Th2-type cytokine production.
AB - An open labeled, phase 1, safety and feasibility study using lymph node extraction, ex vivo lymph node cell expansion, followed by autologous cell reinfusion was evaluated as a potential immunomodulatory treatment strategy in patients with chronic fatigue syndrome (CFS). The experimental therapy utilized the cells of the lymph node, activated and grown in culture with defined media, interleukin-2 (IL-2) and anti-CD3 to activate and enhance cellular immunological functions. This procedure was designed to change the cytokine pattern of the lymph node lymphocytes to favor expression of T-helper (Th)1-type over Th2-type cytokines. The mixed population of ex vivo immune-enhanced cells were reinfused into the donor, who was carefully monitored for adverse events and possible clinical benefit. There were no adverse events. There were significant improvements in clinical status in association with a significant decrease in Th2-type cytokine production.
KW - Autologous lymph node cell transplant
KW - Chronic fatigue syndrome
KW - Cognitive difficulties
KW - Immune activation
KW - Natural killer cells
KW - T-helper type 1 and type 2 cytokines
UR - http://www.scopus.com/inward/record.url?scp=0035074609&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035074609&partnerID=8YFLogxK
U2 - 10.1300/J092v08n01_03
DO - 10.1300/J092v08n01_03
M3 - Article
AN - SCOPUS:0035074609
VL - 8
SP - 39
EP - 55
JO - Journal of Chronic Fatigue Syndrome
JF - Journal of Chronic Fatigue Syndrome
SN - 1057-3321
IS - 1
ER -